APA (7th ed.) Citation

T, P., M, B., B, E., AB, A., MT, B., AY, S., . . . TK, C. (2024). Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO open, 9(5), 102994. https://doi.org/10.1016/j.esmoop.2024.102994

Chicago Style (17th ed.) Citation

T, Powles, et al. "Nivolumab Plus Cabozantinib Versus Sunitinib for First-line Treatment of Advanced Renal Cell Carcinoma: Extended Follow-up from the Phase III Randomised CheckMate 9ER Trial." ESMO Open 9, no. 5 (2024): 102994. https://doi.org/10.1016/j.esmoop.2024.102994.

MLA (9th ed.) Citation

T, Powles, et al. "Nivolumab Plus Cabozantinib Versus Sunitinib for First-line Treatment of Advanced Renal Cell Carcinoma: Extended Follow-up from the Phase III Randomised CheckMate 9ER Trial." ESMO Open, vol. 9, no. 5, 2024, p. 102994, https://doi.org/10.1016/j.esmoop.2024.102994.